503A and 503B A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Poised to Ease Restrictions on Injectable Peptides Af Are Peptides coming off of the FDA Category 2 list? A legal breakdown Holt Law Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law